Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphocyte

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    732 result(s) found for: Lymphocyte. Displaying page 4 of 37.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005830-63 Sponsor Protocol Number: 0485-CL-0004 Start Date*: 2009-10-30
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001098-25 Sponsor Protocol Number: NAC-E-21 Start Date*: 2004-08-23
    Sponsor Name:Zambon SA
    Full Title: N-Acetylcisteine (NAC) effect on the inmunologycal system
    Medical condition: Postmenopausal health woman aged more than 50 years
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-003071-20 Sponsor Protocol Number: C060401 Start Date*: 2005-09-20
    Sponsor Name:FIT Biotech Oyj Plc
    Full Title: Immunogenicity and therapeutic effects of GTU-MultiHIV B clade DNA vaccine. A randomized, controlled, phase II clinical trial in treatment-naive HIV-positive subjects
    Medical condition: Treatment naive HIV infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002155-11 Sponsor Protocol Number: B5411003 Start Date*: 2021-06-09
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE A...
    Medical condition: Moderate and above aplastic anemia
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005553-39 Sponsor Protocol Number: 1501 Start Date*: 2015-12-29
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of Sativex on blood leukocytes in patients with lymphoma/chronic lymphocytic leukaemia
    Medical condition: Lymphoma and chronic lymphocytic leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004429-15 Sponsor Protocol Number: GEM-1402 Start Date*: 2016-02-16
    Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA
    Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma.
    Medical condition: Metastatic uveal melanoma non suitable for radical resection.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002314-31 Sponsor Protocol Number: DLI-TARGET Start Date*: 2018-08-20
    Sponsor Name:Klinikum der Universität München
    Full Title: Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Re...
    Medical condition: Subjects with treatment-resistant mixed chimerism or MRD of CD19+ B-precursor ALL after allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007057-42 Sponsor Protocol Number: A4M108119 Start Date*: 2007-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
    Medical condition: relapsing forms of multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001786-36 Sponsor Protocol Number: ILIAD-7-UK-Cohort Start Date*: 2020-05-06
    Sponsor Name:RevImmune SAS France
    Full Title: Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”
    Medical condition: Lymphopenia and T cell exhaustion in COVID-19 patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003388-79 Sponsor Protocol Number: ML29167 Start Date*: 2014-02-12
    Sponsor Name:Roche Farma, S.A.
    Full Title: PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBINUTUZUMAB (RO5072759) + BENDAMUSTINE TREATMENT IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-005226-11 Sponsor Protocol Number: FIS-TAR-01-2016 Start Date*: 2017-04-04
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase 4 clinical trial, randomized to evaluate the effect on immune recovery of triple antiretroviral maintenance therapy (elvitegravir / cobicistat 150/150 mg + tenofovir + emtricitabine alapenami...
    Medical condition: Adult patients with HIV infection on stable therapy (≥ 6 months) with triple therapy and undetectable viremia for ≥ 1 year.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004848 10049838 HIV viral load undetectable LLT
    19.1 10021881 - Infections and infestations 10077716 HIV viraemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002184-22 Sponsor Protocol Number: NS3 Start Date*: 2021-05-14
    Sponsor Name:Athens Medical Society
    Full Title: A phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 in 10^9 dose versus 10^10 dose, for the prevention of clinical deterioration in pa...
    Medical condition: COVID-19 disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001490-95 Sponsor Protocol Number: ESPRIT 002: STALWART Start Date*: 2006-04-21
    Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID)
    Full Title: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001262-11 Sponsor Protocol Number: FJD-COVID19-20-01 Start Date*: 2020-04-09
    Sponsor Name:Instituto de Investigación Sanitaria Fundación Jiménez Díaz
    Full Title: Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treat...
    Medical condition: COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001573-78 Sponsor Protocol Number: 87RI20_0012 Start Date*: 2020-05-06
    Sponsor Name:RevImmune
    Full Title: Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection
    Medical condition: SARSCo-V-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002157-25 Sponsor Protocol Number: CIVI/2021/ET-01 Start Date*: 2022-11-22
    Sponsor Name:CHU de Nîmes
    Full Title: Description des effets immunologiques périphériques d’un traitement vitamine D à forte dose chez les sujets sains. Essai randomisé monocentrique en double aveugle
    Medical condition: The study population consisted of healthy subjects (women and men) recruited at the University Hospital of Nîmes in order to be comparable in age (± 5 years) and sex (frequency matching) to patient...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004852 10028247 Multiple sclerosis like syndrome LLT
    Population Age: Gender:
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004259-17 Sponsor Protocol Number: NS3.1 Start Date*: 2022-03-02
    Sponsor Name:OBCTCD-24 Ltd
    Full Title: A Phase IIb Randomized, Quadruple-blinded Multicenter, Multinational, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration ...
    Medical condition: COVID-19 disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005582-73 Sponsor Protocol Number: ACE-CL-007 Start Date*: 2015-07-03
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previ...
    Medical condition: Untreated Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005530-64 Sponsor Protocol Number: ACE-CL-006 Start Date*: 2015-07-31
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Ongoing) BE (Completed) FR (Completed) ES (Ongoing) DK (Completed) DE (Completed) PL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:23:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA